Work

Supplementary Figure 1 from Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 167KB, Study patients with advances HNSCC were assigned to three different treatment arms. 'Arm 1' was vaccinated with dendritic cells (DC) loaded with p53-specific peptides (class I) for sequences 149-157 (modified T150L) and 264-272 (modified F270W). In treatment 'arm 2' DC were additionally loaded with tetanus peptide (class II). In treatment 'arm 3' DC were additionally loaded with p53-specific peptides (class II) for sequence 110-124.

DOI: 10.1158/1078-0432.22449264

Authors: Patrick J. Schuler, Malgorzata Harasymczuk, Carmen Visus, Albert DeLeo, Sumita Trivedi, Yu Lei, Athanassios Argiris, William Gooding, Lisa H. Butterfield, Theresa L. Whiteside, Robert L. Ferris

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361827466

Cites:

Cited by:

Related to: 10